<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976922</url>
  </required_header>
  <id_info>
    <org_study_id>H-15012527</org_study_id>
    <nct_id>NCT02976922</nct_id>
  </id_info>
  <brief_title>The Salivary and Faecal Microbiome of Recurrent Aphthous Stomatitis Patients Before and After Treatment With Probiotics</brief_title>
  <official_title>Characterisation of the Salivary and Faecal Microbiome in Patients With Recurrent Aphthous Stomatitis Before and After Treatment With Probiotics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recurrent aphthous stomatitis (RAS) is one of the most common ulcerative diseases affecting&#xD;
      the oral mucosa. The aetiology remains unknown, but several local, systemic, immunologic,&#xD;
      genetic, allergic, nutritional, and microbial factors have been proposed as causative agents.&#xD;
      Clinically, RAS is characterised by recurrent bouts of one or several rounded, shallow,&#xD;
      painful oral ulcers at intervals of a few months or days. The aim of this study is to&#xD;
      characterise the salivary and faecal microbiome in 20 patients with RAS and compare the&#xD;
      findings with those of 20 healthy controls. The study also includes a double-blind randomized&#xD;
      placebo-controlled intervention with probiotics (Lactobacillus reuteri-containing lozenges 2&#xD;
      tablets daily for 3 months) or placebo. The salivary and faecal microbiome in RAS patients is&#xD;
      compared before and after treatment. This study will improve our understanding of the&#xD;
      pathogenesis in RAS and provide us with knowledge on potential future therapeutic approaches.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of the study The purpose of this study is to characterise the salivary and faecal&#xD;
      microbiome in patients with recurrent aphthous stomatitis (RAS) and to compare the findings&#xD;
      to those of a matched healthy control group. Another purpose is to investigate the effect of&#xD;
      treatment with probiotics on the microbiome in whole saliva and faeces as well as the&#xD;
      severity and number of RAS outbreaks. Moreover, a smear will be taken from present aphthous&#xD;
      ulcers before and after treatment with probiotics in order to characterise the local&#xD;
      microbiota.&#xD;
&#xD;
      It is assumed that the microbiome in whole saliva and faeces from patients with RAS (minor or&#xD;
      major type aphthous ulcers) differs from the microbiome in whole saliva and faeces from age-&#xD;
      and gender-matched control persons.&#xD;
&#xD;
      It is also hypothesised that probiotic treatment has a beneficial effect on the mucosal pain&#xD;
      and reduces the severity of RAS and the frequency of outbreaks. Furthermore, it is assumed&#xD;
      that treatment with probiotic has an effect on microbiome in whole saliva and faeces from&#xD;
      patients with RAS.&#xD;
&#xD;
      Background Recurrent aphthous stomatitis (RAS) is one of the most common ulcerative diseases&#xD;
      affecting the oral mucosa. The prevalence varies from 5-25%. The aetiology remains unknown,&#xD;
      but several local, systemic, immunologic, genetic, allergic, nutritional, and microbial&#xD;
      factors have been proposed as causative agents.&#xD;
&#xD;
      Clinically, RAS is characterised by recurrent bouts of one or several rounded, shallow,&#xD;
      painful oral ulcers at intervals of a few months or days.&#xD;
&#xD;
      RAS can be classified into three different types: minor, major and herpetiform. Minor RAS&#xD;
      comprises about 80% of the cases. This type is characterised by aphthous ulcers with a&#xD;
      diameter of about 5 mm, often localised in the buccal and labial mucosa. The ulcers heal&#xD;
      within 7-10 days without formation of scars. Major RAS appear in 10-15% of the patients. The&#xD;
      ulcers are often crateriform with a diameter of 10-30 mm, and typically present on the labial&#xD;
      mucosa, the soft palate, the tonsillar region and oropharynx. The healing time may vary from&#xD;
      2 to 6 weeks and leaving cicatrix. These ulcers are very painful and food intake may be&#xD;
      compromised. The prevalence of the herpetiform type is 5-10%.&#xD;
&#xD;
      This type is often localised in the floor of the mouth and the ventral part of the tongue,&#xD;
      and it characterised by aggregation of multiple small ulcers.&#xD;
&#xD;
      The aetiology remains unknown, but a number of local and systemic factors are assumed&#xD;
      increase the predisposition, including mucosal trauma, stressful events, hormonal changes,&#xD;
      smoking cessation, allergy to various food substances as well as vitamin- and/or mineral&#xD;
      deficiency. The is also a genetic predisposition as the possibility of developing RAS is 90%&#xD;
      if both parents have RAS and 20% if one of the parents has RAS.&#xD;
&#xD;
      Microbial factors A number of microorganisms have been suggested involved in the&#xD;
      aetiopathogenesis of RAS. These include oral streptococci, especially Streptococcus mitis,&#xD;
      but the cross-reaction between oral streptococci and oral mucosal antigens is unspecific and&#xD;
      considered clinically insignificant. Helicobacter pylori, which is associated with gastritis&#xD;
      and duodenal ulcers may also be seen in dental plaque and therefore also be suggested&#xD;
      involved in the pathogenesis of RAS, but the anti-H. pylori seropositivity has not been found&#xD;
      increased in patients with RAS. Various vira have been found in biopsies from aphthous ulcers&#xD;
      such as cytomegalovirus and Epstein-Barr virus. Herpes simplex, varicella zoster and&#xD;
      adenovirus have also been assumed to play a role in the aetiopathogenesis. However, it is has&#xD;
      not been possible to show a causal relationship between virus infection and RAS, and viral&#xD;
      DNA may be present due to a secondary infection.&#xD;
&#xD;
      Novel technologies improve our ability to make more in depth analyses of the microbiota in&#xD;
      patients with RAS. While working on this study protocol one study on the microbiome in&#xD;
      patients with RAS has been published showing an increased proportion of Bacteroides species&#xD;
      in the oral mucosa of patients with RAS compared to healthy controls. Thus, as previous&#xD;
      studies also suggest the oral microbiota appears to play a role in the development of RAS as&#xD;
      well as in perpetuation of RAS.&#xD;
&#xD;
      In this study we will characterise the microbiome in whole saliva, faeces and the aphthous&#xD;
      ulcers of patients with RAS (with active lesions) and analyse how it differs from the&#xD;
      microbiome of healthy subjects. This characterisation could be essential for our&#xD;
      understanding the pathogenesis of RAS and contribute to the development of novel strategies&#xD;
      for managing these patients.&#xD;
&#xD;
      Immunopathological factors Several studies indicate that the pathogenesis of RAS includes a&#xD;
      number of cell-mediated mechanisms, but the exact immunopathogenesis is still not clarified.&#xD;
      Phagocytic and cytotoxic T-lymphocytes may be a role in the destruction of the oral&#xD;
      epithelium and the presence of these immune cells is regulated and maintained by local&#xD;
      release of cytokines. Patients with outbreak of RAS have an increased presence of gamma-delta&#xD;
      T-cells in the blood compared to healthy control persons and patients without active RAS.&#xD;
      Moreover, patients with RAS have an increased presence of Tumour Necrosis Factor (TNF)-alpha&#xD;
      compared to those who do not have RAS, but also other proinflammatory cytokines like&#xD;
      interleukin-2 and -6 are likely to play a role in the pathogenesis of RAS. Finally,&#xD;
      aphthous-like ulcers have been found associated to a number of inflammatory bowel diseases&#xD;
      such as ulcerative colitis and Crohn's disease and celiac disease as well as cyclic&#xD;
      neutropenia, HIV-infection and immunoglobulin A (IgA)-deficiency. Accordingly, an immune&#xD;
      component may be involved in RAS which contribute to a change in the intestinal microbiota or&#xD;
      vice versa. In this study, we will characterise the microbiota in saliva and in faeces from&#xD;
      patients with RAS before, during and after treatment with probiotics.&#xD;
&#xD;
      The study design and methods The project comprises a cross-sectional study which investigates&#xD;
      the microbiome in whole saliva and faeces from 20 patients with RAS and 20 healthy control&#xD;
      persons. The project also includes a double-blind randomized placebo-controlled intervention&#xD;
      with probiotics (Lactobacillus reuteri-containing lozenges 2 tablets daily for 3 months) or&#xD;
      placebo. The salivary and faecal microbiome in RAS patients is compared before and after&#xD;
      treatment.&#xD;
&#xD;
      The patients with RAS are recruited among patients referred to the Oral Medicine Clinic,&#xD;
      Faculty of Health and Medical Sciences, University of Copenhagen. The 20 healthy controls are&#xD;
      recruited via www.forsoegsperson.dk&#xD;
&#xD;
      Methods include:&#xD;
&#xD;
        -  Interview re. onset of RAS, oral symptoms (assessed by means of a visual analogue&#xD;
           scale), comorbidity, medication intake, smoking and alcohol habits, oral hygiene habits.&#xD;
&#xD;
        -  Collection of chewing paraffin-stimulated whole saliva.&#xD;
&#xD;
        -  Oral examination including evaluation of aphthous ulcers (Ulcer Severity Score),&#xD;
           registration of dental status and periodontal status.&#xD;
&#xD;
        -  A smear from one of the aphthous ulcers.&#xD;
&#xD;
        -  A faecal sample will be collected by the subjects themselves in their homes after&#xD;
           thorough instruction and handled according to manual from the Statens Serum Institut.&#xD;
           From the sample 250 mg is collected and kept in a freezer kept at -80Â°C until further&#xD;
           processing and analysis.&#xD;
&#xD;
        -  A blood test including haemoglobin (HgB), C reactive protein (CRP), iron, cobalamin,&#xD;
           folate, transferrin, ferritin and vitamin D levels.&#xD;
&#xD;
      Extraction of bacterial DNA from saliva, faecal and smear samples (at baseline, 7-day and&#xD;
      90-day of intervention with probiotics or placebo, respectively) will be carried out in the&#xD;
      laboratory at Department of Odontology, University of Copenhagen, using previously&#xD;
      established procedures based on instructions from the Human Microbiome Project.&#xD;
&#xD;
      Metagenomic analyses on extracted bacterial DNA from saliva, smear and faecal samples are&#xD;
      made by Beijing Genomics Institute. Illumina 16S rDNA sequencing allows determination of&#xD;
      bacterial taxonomy and phylogenetic diversity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beneficial effect of probiotics on the size of aphthous ulcers and the frequency of RAS outbreaks</measure>
    <time_frame>3 months</time_frame>
    <description>Measurements of the size and numbers of aphthous ulcers (in mm, using scoring system) Baseline (Day 0), Day and after 30 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beneficial effect of probiotics on oral pain related to aphthous ulcers</measure>
    <time_frame>3 months</time_frame>
    <description>Visual analogue pain scale (0-100 mm) Baseline (Day 0), Day 7 and after 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in salivary and faecal microbiome in patients with RAS due to use of probiotics</measure>
    <time_frame>3 months</time_frame>
    <description>Baseline (Day 0), Day 7 and after 30 days: Bacterial DNA extraction and metagenomic analyses on saliva, ulcer smear and faeces</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Recurrent Aphthous Ulcers</condition>
  <arm_group>
    <arm_group_label>Probiotic lozenge</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Probiotic lozenge, one lozenge twice daily for 3 months. The lozenge contains Lactobacilli Reuteri (100 billions colony forming units (CFU)/tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo lozenge, one lozenge twice daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic lozenge</intervention_name>
    <description>10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Probiotic lozenge</arm_group_label>
    <other_name>Biogaia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Patients with recurrent aphthous stomatitis (minor or major aphthous ulcers) and&#xD;
             Caucasians&#xD;
&#xD;
          -  Healthy and non-medicated subjects who match the patients with regard to age and&#xD;
             gender&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Autoimmune diseases/immunosuppressive conditions&#xD;
&#xD;
          -  Treatment with immunosuppressant&#xD;
&#xD;
          -  Current treatment with antibiotics&#xD;
&#xD;
          -  Drug and/or alcohol abuse&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current use of oral rinses&#xD;
&#xD;
          -  Current use of topical steroids or other agents for relief oral symptoms&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathrine Bukkehave, Scholarstip</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Odontology, University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bennett, Assoc Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Odontology, University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Marie Lynge Pedersen, Assoc Prof</last_name>
    <phone>0045 35326500</phone>
    <email>amlp@sund.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Svante Twetman, Professor</last_name>
    <phone>0045 35 68 10</phone>
    <email>stwe@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Odontology, University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Marie Lynge Pedersen, Assoc Prof</last_name>
      <phone>35 32 65 00</phone>
      <phone_ext>0045</phone_ext>
      <email>amlp@sund.ku.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2016</study_first_posted>
  <last_update_submitted>March 11, 2017</last_update_submitted>
  <last_update_submitted_qc>March 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Anne Marie Lynge Pedersen</investigator_full_name>
    <investigator_title>Associate Professor, PhD, DDS</investigator_title>
  </responsible_party>
  <keyword>RAS</keyword>
  <keyword>microbiome</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Stomatitis, Aphthous</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

